Threat detection company Smiths Detection revealed on Wednesday that its BioFlash air sampler can detect the SARS-CoV-2 Alpha variant (B.1.1.7), Beta variant (B.1.351), Gamma variant (P.1), the Kappa variant (B1.617.1), Delta (B.1.617.2) and Delta plus variant (B.1.617.2.1).
The company is currently confirming the ability to detect the Lambda variant, with results likely available in Autumn.
In January 2021, the company announced its BioFlash was capable of detecting airborne SARS-CoV-2 by the US Army of Medical Research Institute of Infectious Diseases (USAMRIID).
BioFlash has successfully been used by several Universities to stop the spread of COVID-19 following airborne detection in several campus buildings, concluded the company.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval